GEA Pharma & Healthcare Insight stories
Customer cases
VESTA® valves in state-of-the-art Korean insulin line
GEA has supplied one of the largest drug manufacturers in Korea with manufacturing equipment for a state-of-the-art pharma production plant. More than 7,000 VESTA® sterile valves were installed to direct the product flow in two identical insulin production lines. This was the first time VESTA® valve technology had been selected to completely equip a new greenfield project. The multimillion Euro order represents the biggest project so far in the history of the VESTA® line.
Caplin Group and GEA Collaborate to Deliver Contained Oncology Plant in Chennai
Caplin Group partners with GEA, a leading supplier of pharmaceutical containment equipment, to establish a state-of-the-art oncology plant in Chennai. Learn how Caplin's expansion plans and GEA's end-to-end solutions will enhance their production capabilities and deliver high-quality medicines.
GEA's Landmark Oncology Contract with Oncogen Pharma in Malaysia
Discover GEA's groundbreaking partnership with Oncogen Pharma in Malaysia, as they secure a multi-million Euro contract for the production of oral solid dosage (OSD) forms to treat cancer. Learn how GEA's end-to-end solutions and innovative technologies overcame challenges during the COVID-19 pandemic, ensuring successful project completion and customer satisfaction.
GEA supports Pfizer to change from batch-based to continuous manufacturing
With the recent inclusion of a suite of fully automated, highly efficient production equipment to manufacture tablets and capsules, Pfizer’s plant in Freiburg, Germany, has been transformed into what the company calls a “Smart Factory.”
Getting Medicines to Patients Faster with POD-Based Mini-Factories
A partnership of pharmaceutical manufacturers and suppliers, including Pfizer, GEA and G-CON Manufacturing, welcomes GSK to a consortium dedicated to the development of a continuous technology solution for on-demand tablet production.
Penn Pharma: Fully Integrated, Contained Tableting
After conducting extensive market research, Penn Pharma identified an increased need in the solid dose oncology market for the outsourced development and production of highly toxic drugs. Its production site had been manufacturing potent solid dosage products for more than 20 years but needed additional capacity.
Project Sprint: Continuous Tablet Manufacturing
Project Sprint provided GEA with an opportunity to collaborate with key customer, supplier and academic groups as part of a strategy to develop a new generation of process intensification systems for drug product development and subsequent manufacturing.
Oncology Manufacturing Line: Zydus Cadila
When GEA supplied a complete oncology manufacturing line to a customer in India, they didn’t just ensure the health and safety of the operators — complying with internationally recognised standards — the company also increased yields, reduced production cycle times and implemented an ultimate containment solution.
